-
Preliminary report outlines 'causal association' between Sanofi's Dengvaxia and 3 deaths
fiercepharma
February 05, 2018
After months of controversy in the Philippines over Sanofi's Dengvaxia, an initial report has found a "causal association" between three deaths and the vaccine. Two of the deaths could have been a result of vaccine failure, according to the Philippine Gen
-
Sanofi, DNDi seek EMA review for sleeping sickness drug
pharmatimes
February 02, 2018
Sanofi has asked European regulators to review an experimental medicine being developed in partnership with the Drugs for Neglected Disease initiative (DNDi) for sleeping sickness, which is endemic in Africa.
-
Newcomer Partner Therapeutics Nabs $60M, Acquires Leukine From Sanofi
biospace
February 02, 2018
Only a week after?launch,?Partner Therapeutics,?or PTx,?acquired?the global rights to Leukine (sargramaostin) from Paris-based?Sanofi.
-
3 FDA Decisions to Look Out for in February
biospace
February 02, 2018
The year is getting off to a good start for?mergers and acquisitions,?with?Sanofi?buying?Bioverativ?for $11.6 billion and?Ablynx?for $4.8 billion,?Celgene?acquiring?Juno Therapeutics?for $9 billion, and?Seattle Genetics?buying?Cascadian Therapeutics?for $
-
Philippines' Department of Health demands full refund of $70m Dengvaxia programme from Sanofi
pharmafile
January 31, 2018
In the latest update of the Sanofi Philippines dengue vaccine scandal, the U.S. Department of Health demanded that French pharmaceutical companies pay a full refund of the three billion Philippine pesos paid by the Philippine government to immunize its ci
-
Ablynx enters €3.9bn acquisition deal with Sanofi
pharmaceutical-technology
January 31, 2018
Belgium-based Ablynx has signed a definitive agreement, under which all of its outstanding shares will be purchased by French firm Sanofi at €45 per share, amounting to a total of about €3.9bn.
-
Sanofi agreed to buy Ablynx for $4.8 B
biospectrumasia
January 30, 2018
The acquisition of Ablynx continues Sanofi's commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules
-
No Deal for Novo as Sanofi Swoops in With $4.85B Win for Ablynx
biospace
January 30, 2018
Only a week after Sanofi ponied up $11.6 billion to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8 billion.
-
Sanofi confirmed the deal to buy Bioverativ for $11.6 B
biospectrumasia
January 24, 2018
The French healthcare company intends to boost its earnings and strengthen its presence in the field of treatments for rare diseases.
-
Sanofi adopts TriNetX platform to speed clinical trials
biospectrumasia
January 24, 2018
Cambridge, MA based TriNetX operates a cloud-accessible federated health research platform.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
